The [^99mTcN(PNP)]²⁺ core offers a unique routefor the preparation of asymmetric ^99mTc-complexes. Though bidentate chelators such as dithiocarbamates are most commonly used ligands in this approach, present study explores the possibility of using a monodentate ligand, a isocyanide derivative of metronidazole (MetroNC), for preparing a ^99mTcN(PNP) complex for detecting tumor hypoxia. MetroNC could be prepared in good yield and subsequently radiolabeled with [^99mTcN(PNP)]²⁺ Precursor complex prepared from [^99mTcN]²⁺ core and N-(2-meth-oxyethyl)-2-(diphenylphosphino)-N-(2-(diphenylphosphino)ethyl)ethanamine (PNP2) ligand. Preliminary biodistribution studies showed tumor uptake pattern similar to previous studies wherein, about 75 % of the tumor activity observed at 60 min post injection (p.i.) was still found to remain in tumor at 180 min p.i.